

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: JENSEN, Martin R. et al. Appl. No.: New

Filed: February 20, 2001 Examiner:

For: NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

February 20, 2001

Sir:

The following preliminary amendments and remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE ABSTRACT:

Please add an Abstract from the Abstract attached hereto.

IN THE CLAIMS:

Please amend the claims as follows:

Claim 5: Line 1, delete "or 4"

Claim 7: Line 1, delete "or 6"

Claim 8: Line 1, change "any one of claims 2-7" to
--claim 2--

Claim 9: Line 1, change "any one of claims 3-8" to
--claim 3--

Claim 10: Line 1, change "any one of claims 3-9" to
--claim 3--

Claim 12: Line 1, change "any one of claims 3-11" to
--claim 3--

Claim 13: Line 1,
--claim 3--

change "any one of claims 3-12" to

Claim 14: Line 1,
--claim 3--

change "any one of claims 3-13" to

Claim 17: Line 1,
claims" to --claim 1--

change "any one of the preceding

Claim 19: Line 1,
claims" to --claim 1--

change "any one of the preceding

Claim 20: Line 1,
claims" to --claim 1--

change "any one of the preceding

Claim 21: Line 1,
claims" to --claim 1--

change "any one of the preceding

Claim 25: Line 1,
claims" to --claim 1--

change "any one of the preceding

Claim 26: Line 1,
claims" to --claim 1--

change "any one of the preceding

Claim 27: Line 1,
claims" to --claim 1--

change "any one of the preceding

Claim 29: Line 1,

delete "or 28"

Claim 30: Line 1,
--claim 1--

change "any one of claims 1-21" to

Claim 33: Line 1,
--claim 22-

change "any one of claims 22-32" to

Claim 34: Lines 4 to 5, change "any one of claims 1-33" to
--claim 1--

Claim 36: Line 2, change "any one of claims 1-19 and
22-24" to --claim 1--

Claim 37: Line 10, delete "or 36"

Claim 38: Line 2, delete "or 36"

Claim 41: Line 1, delete "or 40"

Claim 42: Line 1, change "any one of claims 39-41" to
--claim 39--

Claim 43: Line 1, delete "or 42"

Claim 44: Lines 1 to 2, change "any one of claims 39-43" to -
-claim 39--

Claim 46: Line 1, delete "or 45"; and
Line 3, delete "or 36"

Claim 47: Line 1, change "any one of claims 1-19 and
22-24" to --claim 1--

Claim 48: Line 5: change "any one of claims 39-43" to
--claim 39--

Claim 49: Line 2, change "any one of claims 39-43" to
--claim 39--; and

Line 4, delete "or 36"

Claim 50: Lines 1 to 2, change "any one of claims 44-46" to
--claim 44--; and

Line 4, change "any one of claims 39-43" to
--claim 39--

Claim 53: Line 1, delete "or 52"


REMARKS

The amendment to the claims is merely to delete improper multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32868
Leonard R. Svensson, #30,330

LRS/cqc
3631-0107P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

(Rev. 01/22/01)

ABSTRACT

A method for *in vivo* down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidogenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.